Acute pancreatitis: An overview of emerging pharmacotherapy

BioDrugs

Volumn 10, Issue 5, 1998, Pages 359-371

  Sargen, Kevin ^a   Kingsnorth, Andrew N ^a,b  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIINFECTIVE AGENT; ANTIOXIDANT; APROTININ; ASCORBIC ACID 2 OCTADECYL ETHER; BRADYKININ ANTAGONIST; CATALASE; COMPLEMENT RECEPTOR; CP 0597; GABEXATE MESILATE; GRANULOCYTE COLONY STIMULATING FACTOR; ICATIBANT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LEXIPAFANT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; OCTREOTIDE; PROTEINASE INHIBITOR; SCAVENGER; SOMATOSTATIN; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INJURY; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PANCREAS NECROSIS; PANCREAS PSEUDOCYST; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0031759275     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810050-00003     Document Type: Review

References (133)

1. Bourke JB. Incidence and aetiology of acute pancreatitis. BMJ 1977; 2: 1688-4
2. Corfield AP, Cooper MJ, Williamson RCN. Acute pancreatitis: a lethal disease of increasing incidence. Gut 1985; 26: 724-9
3. Wilson C, Imrie CW. Changing patterns of incidence and mortality from acute pancreatitis in Scotland, 1961-1985. Br J Surg 1990; 77: 731-4
4. Siggurdsson GH. Intensive care management of acute pancreatitis. Dig Surg 1994; 11: 231-41
5. Neoptolemos JP, London NJ, James D, et al. Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. Lancet 1988; ii: 979-83
6. Fan ST, Lai CS, Mok FPT. Early treatment of acute biliary pancreatitis by endoscopic papillotomy. N Engl J Med 1993; 328: 228-32
7. Folsch UR, Nitsche R, Ludtke R, et al. Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. N Engl J Med 1997; 336: 237-42
8. McFadden W, Reber HA. Indications for surgery in severe acute pancreatitis. Int J Pancreatol 1994; 15: 83-90
9. De Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. Gut 1995; 37: 121-6
10. Banks PA. Practice guidelines in acute pancreatitis. Am J Gastroenterol 1997; 92: 377-86
11. Mann DV, Hershman MJ, Hittinger R, et al. Multicentre audit of death from acute pancreatitis. Br J Surg 1994; 81: 890-3
12. Steer ML, Meldolosi J. The cell biology of experimental pancreatitis. N Engl J Med 1987; 316: 144-50
13. Goff JS. The effect of ethanol on the pancreatic duet sphincter of Oddi. Am J Gastroenterol 1993; 88: 656-60
14. Meier P. Who gets and what causes pancreatitis. J Lab Clin Med 1995; 125: 298-300
15. Wedgwood KR, Adler G, Kern H, et al. Effects of oral agents on pancreatic duct permeability: a model of acute alcoholic pancreatitis. Dig Dis Sci 1986; 31: 1081-8
16. Niederau C, Neiderau M, Luthen R, et al. Pancreatic exocrine secretion in acute experimental pancreatitis. Gastroenterology 1990; 99: 1120-7
17. Fernandez del Castillo C, Rattner DW, Warshaw AL. Acute pancreatitis Lancet 1993; 342: 475-9
18. Kingsnorth AN. Role of cytokines and their inhibitors in acute pancreatitis. Gut 1997; 40: 1-4
19. Sweiry JH, Mann GE. Role of oxidative stress in the pathogenesis of acute pancreatitis. Scand J Gastroenterol 1996; S219: 10-5
20. Weidenbach H, Lerch MM, Gress TM, et al. Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis. Gut 1995; 37: 434-40
21. Kusske AM, Rongione AJ, Reber HA. Cytokines and acute pancreatitis. Gastroenterology 1996; 110 (2): 639-42
22. Formela L, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br J Surg 1995; 82: 6-13
23. Rink L, Kirchner H. Recent progress in the tumor necrosis factor-α field. Allergy Immunol 1996; 111: 199-209
24. 2 generation and neutrophil accumulation in rat lungs after acute necrotizing pancreatitis. Surgery 1995; 118: 547-54
25. Horton JW. Haemodynamic function in acute pancreatitis. Surgery 1988; 103: 538-46
26. Guice K, Oldham KT, Johnson KJ, et al. Pancreatitis induced lung injury. Ann Surg 1988; 208: 71-7
27. Isenmann R, Buchler MW. Infection and acute pancreatitis. Br J Surg 1994; 81: 1707-8
28. Cox AG. Death from acute pancreatitis. MRC multicentre trial of glucagon and apoprotin. Lancet 1977; 24: 632-5
29. Imrie CW, Benjamin IS, Ferguson JC, et al. A single centre double blind trial of trasylol therapy in acute pancreatitis. Br J Surg 1978; 65: 337-341
30. Ohshio G, Saluja AK, Leli U, et al. Esterase inhibitors prevent lysosomal enzyme redistribution in two non-invasive models of experimental pancreatitis. Gastroenterology 1989; 96: 853-9
31. Wisner JR, Renner IG, Grendell JU, et al. Gabexate mesilate (FOY) protects against ceauletide-induced pancreatitis in the rat pancreas. Pancreas 1987; 2: 181-6
32. Buchler M, Malfertueiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993; 104: 1165-70
33. Pederloui P, Gavallini G, Falconi M, et al. Gabexate mesilate versus aprotonin in human acute pancreatitis (GAMEPA). Int J Pancreatol 1993; 14: 117-24
34. Messori A, Rampallo R, Scrollaro G, et al. Effectiveness of gabexate mesilate in acute pancreatitis. Dig Dis Sci 1995; 40: 734-8
35. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996; 335: 919-23
36. Russell RCG. Somatostatin in pancreatic disease. Br J Surg 1996; 83: 1665-7
37. Gullo L, Priory P, Scarpilnato C, et al. Effect of somatostatin 14 on pure human pancreatic secretion. Dig Dis Sci 1987; 32: 1065-70
38. Baxter JN, Ellenbogen S, Roberts N, et al. The effects of a somatostatin analogue SMS 201-995 on pancreatic secretion in pig and man. Surg Res Commun 1988; 4: 215-28
39. Niederau C, Niederau M, Lutuen R, et al. Pancreatic exocrine secretion in acute experimental pancreatitis. Gastroenterology 1990; 99: 1120-7
40. Kotzampassi K, Eleftheriadis E. Octreotide and pancreatic perfusion on the outcome of experimental acute pancreatitis. Dig Surg 1996; 13: 460-4
41. Schwades U, Althoff PH, Klempa I, et al. Effects of somatostatin on bile induced haemorrhagic pancreatitis in the dog Horm Metab Res 1979; 11: 655-61
42. Baxter JN, Jenkins SA, Cowell DC, et al. Effects of somatostatin and a long acting somatostatin analogue on the prevention and treatment of experimentally induced pancreatitis in the rat. Br J Surg 1985; 72: 382-5
43. Scuarlman DE, Beinfeld MC, Andros C, et al. Effects of somatostatin on acute canine pancreatitis. Int J Pancreatol 1987; 2: 247-55
44. Lankisch PC, Koop H, Winckler K, et al. Somatostatin therapy of acute experimental pancreatitis. Gut 1977; 18: 713-6
45. Paran H, Neufeld D, Mayo A, et al. Preliminary report of a prospective randomised study of octreotide in the treatment of severe acute pancreatitis. J Am Coll Surg 1995; 181: 121-4
46. Cuoi TK, Mok F, Zuan WH, et al. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut 1989; 30: 223-7
47. Gjrup I, Roikjaer O, Amderven B, et al. A double blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynaecol Obstet 1992; 175: 397-400
48. D'Amilo D, Favia G, Biasiato R, et al. The use of somatostatin in acute pancreatitis results of a multicentre trial. Hepatogastroenterology 1990; 37: 92-8
49. Binmueller KF, Harris AG, Dumas R, et al. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis. Gut 1992; 33: 1129-33
50. Dabrowski A, Chwiecko M. Oxidative stress: an early phenomenon characteristic of acute experimental pancreatitis. Int J Pancreatol 1992; 12: 193-9
51. Braganza JM, Scott P, Bilton D, et al. Evidence for early oxidative stress in acute pancreatitis. Int J Pancreatol 1995; 17: 69-81
52. Nonaka A, Manabe T, Tobe T. Effect of a new synthetic ascorbic acid derivative as a free radical scavenger on the development of acute pancreatitis in mice. Gut 1991; 32: 528-32
53. Wisner J, Renner IG. Allopurinol attenuates caerulein induced acute pancreatitis in the rat. Gut 1988; 29: 926-9
54. Neiderau C, Neiderau M, Borchard F, et al. Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis. Pancreas 1992; 7: 486-96
55. Steer ML, Rutledge PL, Powers RE, et al. The role of oxygen derived free radicals in two models of experimental acute pancreatitis: effects of catalase, superoxide dismutase, dimethylsulfoxide, and allopurinol. Klin Wochenschr 1991; 69: 1012-7
56. Lankisch PG, Pohl U, Otto J. Xanthine oxidase inhibitor in acute experimental pancreatitis in rats and mice. Pancreas 1989; 4: 436-40
57. Hotter G, Closa D, Gelpi E, et al. Role of xanthine oxidase and eicosanoids in development of pancreatic ischaemia-reperfusion injury. Inflammation 1995; 4: 469-78
58. Wisner J, Green D, Ferrell L, et al. Evidence for a role of oxygen free radicals in the pathogenesis of caerulein induced acute pancreatitis in rats. Gut 1988; 29: 1516-23
59. Wang XD, Deng XM, Haraldsen R, et al. Antioxidant and calcium channel blockers counteract endothelial barrier injury induced by acute pancreatitis in rats. Scand J Gastroenterol 1995; 30: 1129-36
60. Furukawa M, Kimura T, Yamaguchi H, et al. Role of oxygen-derived free radicals in hemorrhagic pancreatitis induced by stress and caerulein in rats. Pancreas 1994; 9: 67-72
61. Schoenberg MH, Buchler M, Younes M. Effect of antioxidant treatment in rats with acute hemorrhagic pancreatitis. Dig Dis Sci 1994; 39: 1034-40
62. Schoenberg MH, Birk D, Beger HG. Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr 1995; 62: 1306-14
63. Yotsumoto F, Manabe T, Ohshio G. Bradykinin involvement in the aggravation of acute pancreatitis in rabbits. Digestion 1993; 54: 224-30
64. Klar E, Messmer K, Warshaw AL, et al. Pancreatic ischaemia in experimental acute pancreatitis: mechanism, significance and therapy. Br J Surg 1990; 77: 1205-10
65. Griesbacher T, Tiran B, Lembeck F. Pathological events in experimental acute pancreatitis prevented by the bradykinin antagonist, Hoe 140. Br J Pharmacol 1993; 108: 405-11
66. Hoffman TF, Leider R, Waldner H, et al. Bradykinin antagonists HOE-140 and CP-0597 diminish microcirculatory injury after ischaemia-reperfusion of the pancreas. Br J Surg 1996; 83: 189-95
67. Hottman TF, Waldner H, Messmer K. The bradykinin antagonist CP-0597 can limit the progression of postischaemic pancreatitis. Immunopharmacology 1996; 33: 243-6
68. Kanbe T, Naruse S, Kitagawa Y. Effects of a bradykinin receptor antagonist (HOE140) on taurochlorate induced acute pancreatitis in rats. Pancreas 1996; 13: 283-8
69. Lerch MM, Weidenbach H, Gress TM, et al. Effect of kinin inhibition in experimental acute pancreatitis. Am J Physiol 1995; 269: G490-9
70. Schmidt HW, Walter U. NO at work. Cell 1994; 78: 919-25
71. Konturek SJ, Bilski J, Konturek PK, et al. Role of endogenous nitric oxide in the control of canine pancreatic secretion and blood flow. Gastroenterology 1993; 104: 896-902
72. Holst JJ, Rasmussen TN, Schmidt P. Role of nitric oxide in neurally induced pancreatic exocrine secretion in pigs. Am J Physiol 1994; 266: 206-13
73. Konturek JW, Hengst K, Kulesza E. Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion in humans. Gut 1997; 40: 86-91
74. Molero X, Guarner F, Salas A. Nitric oxide modulates pancreatic basal secretion and response to cerulein in the rat: effects in acute pancreatitis. Gastroenterology 1995; 108: 1855-62
75. Werner J, Rivera J, Fernandez del Castillo C. Differing roles of nitric oxide in the pathogenesis of acute endematous versus necrotising pancreatitis. Surgery 1997; 121: 23-30
76. Abe T, Shimosegawa T, Satoh A, et al. Nitric oxide modulates pancreatic edema formation in rat caerulein-induced pancreatitis. J Gastroenterol 1995; 30: 636-42
77. Dobosz M, Hac S, Wajda Z. Does nitric oxide protect from microcirculatory disturbances in experimental acute pancreatitis in rats. Int J Microcirc 1996; 16: 221-6
78. Jolliet P, Bulpa P, Ritz M, et al. Additive beneficial effects of the prone position, nitric oxide, and almatrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome. Crit Care Med 1997; 25: 786-94
79. O'Donovan DA, Kelly CJ, Abdih H, et al. Role of nitric oxide in lung injury associated with experimental acute pancreatitis. Br J Surg 1995; 82: 1122-6
80. Tsukahara Y, Horita Y, Anan K. Role of nitric oxide derived from alveolar macrophages in the early phase of acute pancreatitis. J Surg Res 1996; 66: 43-50
81. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994; 343: 1199-206
82. Crane B, Arvai AS, Gachhui R. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science 1997; 278: 425-31
83. Van der Poll T, Lowry SF. Tumour necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense. Shock 1995; 3 (1): 1-12
84. De Beux AC, Ross JA, Maingay JP, et al. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis. Br J Surg 1997; 83: 1071-5
85. Exley AR, Leese T, Holliday MP, et al. Endotoxaemia and serum tumour necrosis factor as prognostic markers in severe acute pancreatitis. Gut 1992; 33: 1126-8
86. McKay CJ, Gallagher G, Brooks B, et al. Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. Br J Surg 1996; 83: 919-23
87. De Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996; 83: 349-53
88. Norman JG, Fink GW, Franz MG. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch Surg 1995; 130: 966-70
89. Gukovskaya AS, Gukovsky I, Zaninovic V, et al. Pancreatic acinar cells produce, release, and respond to tumour necrosis factor-α. J Clin Invest 1997; 100 (7): 1853-62
90. Grewal HP, Mohey el-Din AB, Gaber LW, et al. Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-α 9 polyclonal antibody. Am J Surg 1994; 167: 214-8
91. Hughes CB, Gaber LW, Mohey el-Din AB, et al. Inhibition of TNF-α improves survival in an experimental model of acute pancreatitis. Am Surg 1996; 62 (1): 8-13
92. Guice KS, Oldham KT, Remick DG, et al. Antitumor necrosis factor antibody augments edema formation in caeruline induced acute pancreatitis. J Surg Res 1991; 51: 495-9
93. Norman JG, Fink GW, Messina J, et al. Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surgery 1996; 120: 515-21
94. Havell EA. Evidence that TNF has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-9
95. Platanias LC, Vogelzang NJ. Interleukin-1: biology, pathophysiology, and clinical prospects. Am J Med 1990; 89: 621-9
96. Norman JG, Fink GW, Franz MG, et al. Active interleukin-1 receptor required for maximal progression of acute pancreatitis. Ann Surg 1996; 223 (2): 163-9
97. Dower SK, Fanslow W, Jacobs C, et al. Interleukin-1 antagonists. Ther Immunol 1994; 1: 113-22
98. Norman JG, Franz MG, Messina J, et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995; 117: 648-55
99. Fink GW, Yang J, Carter G, et al. Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. J Surg Res 1997; 67: 94-7
100. Norman JG, Franz MG, Fink GW, et al. Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg 1995; 221 (6): 625-34
101. Tanaka K, Murata A Uda K, et al. Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute narcotising pancreatitis. Crit Care Med 1995; 23 (5): 901-8
102. Norman J, Yang J, Fink G, et al. Severity and mortality of experimental pancreatitis are dependent on interleukin-1 converting enzyme (ICE). J Inteferon Cytokine Res 1997; 17: 113-8
103. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol 1994; 1: 173-85
104. Howard M, Muchamuel T, Andrade S, et al. Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 1993; 117: 1205-9
105. Van der Poll T, Jansen PM, Montegut WJ, et al. Effects of Interleukin-10 on systemic inflammatory responses during sublethal primate endotoxaemia. J Immunol 1997; 158: 1971-5
106. Van Leetham J, Marchant A, Delvaux A, et al. Interleukin-10 prevents necrosis in murine experimental acute pancreatitis. Gastroenterology 1995; 108: 1917-22
107. Rongione AJ, Kusske AM, Kwan K. Interleukin-10 reduces the severity of acute pancreatitis in rats. Gastroenterology 1997; 112: 960-7
108. Kusske AM, Rongione AJ, Ashley SW, et al. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. Surgery 1996; 120: 284-9
109. Formela LJ, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br J Surg 1995; 82: 6-13
110. Braquet P, Touqui L, Shen TY, et al. Perspectives in platelet activating factor research. Pharmacol Rev 1987; 39: 97-145
111. Emmanuelli G, Montrucchio G, Gaia E, et al. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol 1989; 134: 315-26
112. Formela LJ, Wood LM, Whittaker M, et al. Amelioration of acute pancreatitis in a rat model by a potent platelet activating factor antagonist. Br J Surg 1994; 81: 1783-5
113. Zhou W, McCollum MO, Levine BA, et al. Role of platelet activating factor in pancreatitis associated lung injury in the rat. Am J Pathol 1992; 140: 971-9
114. Galloway SW, Kingsnorth AN. Lung injury in a microembolic model of acute pancreatitis. Pancreas 1996; 13: 140-6
115. Kingsnorth AN, Galloway SW, Formela LJ. Randomised double blind phase II trial of lexipafant, a platelet activating factor antagonist, in human acute pancreatitis. Br J Surg 1995; 82: 1414-20
116. McKay C, Curran F, Sharples C, et al. Prospective, placebo-controlled, randomised trial of lexipafabt in predicted severe acute pancreatitis. Br J Surg 1997; 84: 1239-43
117. Kingsnorth AN. British Acute Pancreatitis Study Group. Early treatment with lexipafant, a platelet activating factor antagonist, reduces mortality in acute pancreatitis: a double blind, randomised placebo controlled study [abstract]. Gastroenterology 1997; 112 Suppl. 1: 453A
118. Beger HG, Bittner R, Block S, et al. Bacterial contamination of pancreatic necrosis. Gastroenterology 1986; 91: 433-8
119. Isenmann R, Buchler MW, Friess H, et al. Antibiotics in acute pancreatitis. Dig Surg 1996; 13: 365-9
120. Banks PA. Practice guidelines in acute pancreatitis. Am J Gastroenterol 1997; 92: 377-86
121. Johnson CD. Antibiotic prophylaxis in acute pancreatitis. Br J Surg 1996; 83: 883-4
122. Craig RM, Durdal E, Myles L. The use of ampicillin in acute pancreatitis. Ann Intern Med 1975; 83: 831-2
123. Buchler M, Malfertheiner P, Friess H, et al. Human pancreatic tissue concentration of bacterial antibiotics. Gastroenterology 1992; 103: 1902-8
124. Gianotti L, Munda R, Genneri R, et al. Effect of different specimens of gut decontamination of bacterial translocation and mortality in experimental acute pancreatitis. Eur J Surg 1995; 161: 85-92
125. Luiten EJT, Hopth WCJ, Lance JF, et al. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995; 222: 57-65
126. Pederzollli P, Bassi C Vesentini S, et al. A randomised multicenter clinical trial of antibiotic prophylaxis of septic complications in acute necrotizing pancreatitis with imipenem. Surg Gynaecol Obstet 1993; 176: 480-3
127. Sainio V, Kemppainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346: 663-7
128. Weiser MR, Gibbs SAL, Moore FD, et al. Complement inhibition by soluble complement receptor type I fails to moderate cerulein induced pancreatitis in the rat. Int J Pancreatol 1996; 19: 129-34
129. Yagamuchi H, Weidenback H, Luhrs H, et al. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe experimental acute pancreatitis. Gut 1997; 40: 531-55
130. Rao R, Prinz PA, Kazantsev GB, et al. Effect of granulocyte colony stimulating factor in severe pancreatitis. Surgery 1996; 119: 657-63
131. Chen YZ, Yamaguchi Y, Sameshima H, et al. The protective effects of long acting recombinant human pancreatic secretory trypsin inhibitor (R44S-PST1) in a rat model of cerulein induced pancreatitis. J Int Med Res 1996; 24: 59-68
132. Banerjee AK, Galloway SJ, Kingsnorth AN. Experimental models of acute pancreatitis. Br J Surg 1994; 81: 1096-103
133. Steinberg WM, Schlesselman SE. Treatment of acute pancreatitis: comparison of animal and human studies. Gastroenterology 1987; 93: 1420-7